

WEST

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

Search Results - Record(s) 1 through 13 of 13 returned. 1. Document ID: US 6245800 B1

L2: Entry 1 of 13

File: USPT

Jun 12, 2001

US-PAT-NO: 6245800

DOCUMENT-IDENTIFIER: US 6245800 B1

TITLE: Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine

DATE-ISSUED: June 12, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Arduini; Arduino	Rome	N/A	N/A	ITX
Peschecchia; Alessandro	Ostia Lido	N/A	N/A	ITX
Carminati; Paolo	Milan	N/A	N/A	ITX

US-CL-CURRENT: 514/419; 514/460, 514/510, 514/642 2. Document ID: US 6217898 B1

L2: Entry 2 of 13

File: USPT

Apr 17, 2001

US-PAT-NO: 6217898

DOCUMENT-IDENTIFIER: US 6217898 B1

TITLE: Pharmaceutical composition comprising carnitine or alkanoyl L-carnitine, for the prevention and treatment of diseases brought about by lipid metabolism disorders

DATE-ISSUED: April 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cavazza; Claudio	Rome	N/A	N/A	ITX

US-CL-CURRENT: 424/450; 424/451, 424/464, 424/489, 514/557, 514/824

 3. Document ID: US 6180680 B1

L2: Entry 3 of 13

File: USPT

Jan 30, 2001

US-PAT-NO: 6180680

DOCUMENT-IDENTIFIER: US 6180680 B1

TITLE: Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism

DATE-ISSUED: January 30, 2001

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Cavazza; Claudio

Rome

N/A

N/A

ITX

US-CL-CURRENT: 514/642; 514/451, 514/460

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KOMC	Drawn Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	------------------------	----------------------	----------------------------	-----------------------

 4. Document ID: US 5994581 A

L2: Entry 4 of 13

File: USPT

Nov 30, 1999

US-PAT-NO: 5994581

DOCUMENT-IDENTIFIER: US 5994581 A

TITLE: Carnitine creatinate

DATE-ISSUED: November 30, 1999

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Fang; Sen-Maw

North Salt Lake

UT

N/A

N/A

US-CL-CURRENT: 562/560; 562/567

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KOMC	Drawn Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	------------------------	----------------------	----------------------------	-----------------------

 5. Document ID: US 5571518 A

L2: Entry 5 of 13

File: USPT

Nov 5, 1996

US-PAT-NO: 5571518
DOCUMENT-IDENTIFIER: US 5571518 A

TITLE: Cosmetic compositions containing tricholine citrate

DATE-ISSUED: November 5, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pillai; Sreekumar	Wayne	NJ	N/A	N/A
Mahajan; Manisha N.	Edgewater	NJ	N/A	N/A
Rawlings; Anthony V.	Wyckoff	NJ	N/A	N/A

US-CL-CURRENT: 424/401; 424/59, 424/70.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	------------------------	---------------------	---------------------------	-----------------------

6. Document ID: US 5108767 A

L2: Entry 6 of 13 File: USPT Apr 28, 1992
US-PAT-NO: 5108767
DOCUMENT-IDENTIFIER: US 5108767 A

TITLE: Liquid nutritional product for persons receiving renal dialysis

DATE-ISSUED: April 28, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mulchandani; Rohini P.	Worthington	OH	N/A	N/A
Gluvna; Judith A.	Columbus	OH	N/A	N/A
Knisley; Tina M.	Reynoldsburg	OH	N/A	N/A
Cockram; David B.	Hilliard	OH	N/A	N/A

US-CL-CURRENT: 426/72; 426/590, 426/656, 426/657, 426/73, 426/74, 514/2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	------------------------	---------------------	---------------------------	-----------------------

7. Document ID: US 4921877 A

L2: Entry 7 of 13 File: USPT May 1, 1990

US-PAT-NO: 4921877
DOCUMENT-IDENTIFIER: US 4921877 A

TITLE: Liquid nutritional formula for glucose intolerance

DATE-ISSUED: May 1, 1990

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cashmere; Karen A.	Columbus	OH	N/A	N/A
Besozzi; Elizabeth M.	Columbus	OH	N/A	N/A

US-CL-CURRENT: 424/439; 426/601, 426/801, 514/904

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KIMC](#) | [Draw Desc](#) | [Image](#)

8. Document ID: US 4784992 A

L2: Entry 8 of 13

File: USPT

Nov 15, 1988

US-PAT-NO: 4784992

DOCUMENT-IDENTIFIER: US 4784992 A

TITLE: Phosphorylalkanolamide derivatives of L-carnitine and pharmaceutical compositions containing same

DATE-ISSUED: November 15, 1988

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Reiner; Alberto	Como	N/A	N/A	ITX

US-CL-CURRENT: 514/77; 558/170, 987/224

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KIMC](#) | [Draw Desc](#) | [Image](#)

9. Document ID: US 4528197 A

L2: Entry 9 of 13

File: USPT

Jul 9, 1985

US-PAT-NO: 4528197

DOCUMENT-IDENTIFIER: US 4528197 A

TITLE: Controlled triglyceride nutrition for hypercatabolic mammals

DATE-ISSUED: July 9, 1985

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blackburn; George L.	Cambridge	MA	N/A	N/A

US-CL-CURRENT: 514/552

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Drawn Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	------------------------	---------------------	----------------------------	-----------------------

10. Document ID: US 4315944 A

L2: Entry 10 of 13

File: USPT

Feb 16, 1982

US-PAT-NO: 4315944

DOCUMENT-IDENTIFIER: US 4315944 A

TITLE: Pharmaceutical composition comprising L-carnitine for the treatment of hyperlipidaemias and hyperlipoproteinaemias

DATE-ISSUED: February 16, 1982

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Ramacci; Maria T.

Rome

N/A

N/A

ITX

US-CL-CURRENT: 514/561

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Drawn Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	------------------------	---------------------	----------------------------	-----------------------

11. Document ID: US 4268524 A

L2: Entry 11 of 13

File: USPT

May 19, 1981

US-PAT-NO: 4268524

DOCUMENT-IDENTIFIER: US 4268524 A

TITLE: Method of treating abnormal lipoprotein ratios with acylcarnitine

DATE-ISSUED: May 19, 1981

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Cavazza; Claudio

00144 Rome

N/A

N/A

ITX

US-CL-CURRENT: 514/533; 514/547, 514/556

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Drawn Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	------------------------	---------------------	----------------------------	-----------------------

12. Document ID: US 4255449 A

L2: Entry 12 of 13

File: USPT

Mar 10, 1981

US-PAT-NO: 4255449
 DOCUMENT-IDENTIFIER: US 4255449 A

TITLE: Method of treating abnormal lipoprote in ratios

DATE-ISSUED: March 10, 1981

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cavazza; Claudio	Chiasso	N/A	N/A	CHX

US-CL-CURRENT: 514/554

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KIMC](#) | [Drawn Desc](#) | [Image](#)

13. Document ID: AU 200058474 A, WO 200107038 A2

L2: Entry 13 of 13

File: DWPI

Feb 13, 2001

DERWENT-ACC-NO: 2001-182712

DERWENT-WEEK: 200128

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Use of L-carnitine and lower alkanoyl derivatives for treating patients with diabetic and/or dysmetabolic nephropathy or chronic kidney failure

INVENTOR: CAVAZZA, C; VALENTINI, G

PRIORITY-DATA: 1999IT-RM00480 (July 27, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 200058474 A	February 13, 2001	N/A	000	A61K031/205
WO 200107038 A2	February 1, 2001	E	013	A61K031/205

INT-CL (IPC): A61K 31/205

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KIMC](#) | [Drawn Desc](#) | [Image](#)

[Generate Collection](#)

Terms	Documents
(carnitine same triglyceride\$) same (reduction or reduc\$\$\$\$ or lower\$\$\$\$)	13

[Display](#)

[30](#)

Documents, starting with Document:

[13](#)

Display Format: CIT Change Format

WEST

[Help](#) [Logout](#) [Interrupt](#)

[Main Menu](#) [Search Form](#) [Posting Counts](#) [Show S Numbers](#) [Edit S Numbers](#) [Preferences](#)

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

starting with: LOWER\$\$\$\$(LOWERPARTIAL).P28-P86,P23-P27,P20-P22,P1-P18,P19-P19.

Search Results -

Terms	Documents
(carnitine same triglyceride\$) same (reduction or reduc\$\$\$\$ or lower\$\$\$\$)	13

Database: US Patents Full-Text Database US Pre-Grant Publication Full-Text Database JPO Abstracts Database EPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins

Search History

Today's Date: 6/27/2001

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,JPAB,EPAB,DWPI,TDBD	(carnitine same triglyceride\$) same (reduction or reduc\$\$\$\$ or lower\$\$\$\$)	13	<u>L2</u>
USPT,JPAB,EPAB,DWPI,TDBD	carnitine same triglyceride\$	89	<u>L1</u>

WEST **Generate Collection**

L2: Entry 12 of 13

File: USPT

Mar 10, 1981

DOCUMENT-IDENTIFIER: US 4255449 A

TITLE: Method of treating abnormal lipoprote in ratios

BSPR:

The report of Gemelli et al., *supra*, that carnitine lowers plasma cholesterol levels in healthy infants is, as noted, not readily reconciled with the work of Strack et al., *supra*, and Frohlich et al., *supra*. It has been found for example that, in agreement with Gemelli et al., in normal rats, after a single administration of carnitine at dose levels of 50-100 mg/kg and 400 mg/kg orally, intraperitoneally, intravenously and subcutaneously, cholesterol plasma levels were reduced. However in contrast to the findings of Gemelli et al. where the level of triglycerides and free fatty acids were not affected, it has been found that a decrease in triglycerides and free fatty acids does occur upon the administration of carnitine. Moreover and quite surprisingly it has been found that the level of certain fractions of lipoproteins are actually increased upon administration of carnitine and that it is the relative level of these in the plasma rather than the gross level of plasma cholesterol which is therapeutically significant. In fact, a mere reduction in gross plasma cholesterol levels may be detrimental, as is discussed in greater detail hereafter.

BSPR:

Moreover, it does not appear that carnitine has any significant effect on triglyceride levels when these are at normal levels. The increase in HDL levels and the reduction of the (LDL+VLDL)/HDL ratio upon the administration of carnitine occurs rather only when the ratio is abnormally high. Typically, a normal ratio in man is about 1.5-2.7.

BSPR:

As can be seen, administration of carnitine (D,L) at a 1000 mg in a multiple dose regimen of 500 mg b.i.d. to hyperlipidemic patients for 28-30 days effected a reduction in the (LDL+VLDL)/HDL ratio from 3.4.+-0.12 to 2.8.+-0.89, a decrease of 16.7%. This reduction was accompanied by reductions of 20.6% total lipids, 10.5% cholesterol and 12.8% triglycerides.

WEST

L2: Entry 11 of 13

File: USPT

May 19, 1981

DOCUMENT-IDENTIFIER: US 4268524 A

TITLE: Method of treating abnormal lipoprotein ratios with acylcarnitine

BSPR:

In contrast to the findings of Gemelli et al, supra where the level of triglycerides and free fatty acids were not affected by carnitine per se, it has been found that a decrease in triglycerides and free fatty acids occurs upon the administration of acylcarnitine. Moreover, and quite surprisingly, it has been found that the level of certain fractions of lipoproteins are actually increased upon administration of acylcarnitine and that it is the relative level of these in the plasma, rather than the gross level of plasma cholesterol, which is therapeutically significant. In fact, a mere reduction in gross plasma cholesterol levels may be detrimental, as is discussed in greater detail hereafter.

WEST **Generate Collection**

L2: Entry 10 of 13

File: USPT

Feb 16, 1982

DOCUMENT-IDENTIFIER: US 4315944 A

TITLE: Pharmaceutical composition comprising L-carnitine for the treatment of hyperlipidaemias and hyperlipoproteinaemias

DEPR:

Triglyceride and cholesterol levels were reduced (FIG. 2) and the formation of plasma acyl carnitine was increased. This effect was in no case present in the animals treated with D-carnitine, thus demonstrating the high selectivity of L-carnitine in the activities involving the mechanisms correlated to lipid metabolism, particularly lipoprotein metabolism.

DEPR:

Male patient, 54 years of age, affected by primary hypertension; hypertriglyceridaemia accompanied by remarkably increased .beta.-lipoproteins was ascertained upon hospitalization. Hypertension was treated with a diuretic only. When normal pressure was re-established, hyperlipidaemia was treated with L-carnitine 1 g per day in three 330-mg administrations. Prior to L-carnitine treatment the patient was given an appropriate isocaloric diet in the attempt to change the hyperlipidaemic pattern for the duration of the entire antihypertensive treatment, i.e. 29 days. The diet had moderately lowered triglyceride. Therefore the patient was defined as being resistant to the diet and L-carnitine treatment was commenced. Blood was sampled in basal conditions and on the 21st day. The decrease in triglyceride is evident and values are practically normal. The .beta./.alpha.-lipoprotein ratio is substantially normal.

DEPR:

Male diabetic patient, 55 years of age, hospitalized for sequelae of hemiplegia. Hypoglycaemizing agents were administered to the patient via the oral route until a return to normal glyceamia and therapy was continued at minimum doses. However, the lipid pattern was markedly pathological in spite of hypoglycaemizing and dietetic treatment. The decision was taken to start L-carnitine therapy at the regimen of 1.33 g daily in four 330-mg (approx.) administrations. Treatment was continued for 4 weeks and blood was analyzed in basal conditions and on the 28.sup.th day. Triglyceride and total cholesterol were remarkably lowered with a decreased .beta./.alpha.-lipoprotein ratio at the end of therapy.